New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
09:06 EDTPTNPalatin Tech to benefit from FDA request, says Roth Capital
After the FDA requested more data about Sprout Pharmaceuticals' female sexual dysfunction drug, Roth Capital thinks the FDA's request solidifies the path forward for female sexual health drugs overall. The firm thinks the FDA's request will help Palatin's bremelanotide for the treatment of female sexual dysfunction ,and it keeps a "Buy rating on the stock.
News For PTN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PTN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use